McLoughlin Margi

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Strata Oncology, Inc. manufactures oncology drugs. It provides comprehensive testing, portfolio of treatments, peace of mind. The company was founded by Daniel D. Rhodes, Scott Tomlin and Keith T. Flaherty in 2015 and is headquartered Ann Arbor, MI.

Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada.

Arkuda Therapeutics, Inc. engages in development of medicines to improve the lives of patients with neurological diseases. It leverages insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. The company was founded by Gerhard Koenig and Duane Burnett in 2018 and is headquartered in Cambridge, MA.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA.

Incendia Therapeutics, Inc. develops a novel class of anti-cancer therapies. The company is based in Boston, MA. The company was founded in 2003 by Laurent Audoly, Colin Glenn Begley, Olga Granaturova, Guy Travis Clifton. Laurent Audoly has been the CEO since 2003.

Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

Montis Biosciences BV engages in the development of immune-oncology therapeutics targetting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It offers target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded by Peter Carmeliet and Massimiliano Mazzone and is headquartered in Meise, Belgium.

Reflexion Medical, Inc. develops medical devices. Its products include marketwired resonate and influencers, news distribution, IR and PR hosted newsroom and media database. The company was founded by Akshay Nanduri and Samuel Mazin in 2009 and is headquartered in Hayward, CA.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX.

Mitokinin, Inc. develops kinase neo-substrates for the treatment of neurodegenerative and mitochondrial diseases. The company was founded by Kevan Shokat, Nicholas Hertz, and Daniel de Roulet Jr. and is headquartered in New York, NY.

Kestrel Therapeutics, Inc. operates as a biotechnology development company. The company is based in Wayland, MA. The CEO of the company is Frank G. Haluska.

EvolveImmune Therapeutics Inc. engages in the provision of healthcare services. It offers immunotherapy platform to develop molecules for the treatment of oncology and immune diseases. The company was founded in 2019 and is headquartered in Westport, CT.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA.

Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.

Entrepreneurship Lab NYC is an entrepreneurship education and networking program that was founded in 2012. The program focuses on first-time founders with prior entrepreneurship education and is centered around bio and health tech. The goal of the program is to provide these founders with the basic skills and knowledge they need to succeed in their entrepreneurial endeavors.

Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington.

Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022.

Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA.

FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.

Lodo Therapeutics Corp. engages in the development of novel therapeutics from its metagenomics-based small molecule discovery platform. Its Lodo platform leverages breakthroughs in next-generation sequencing (NGS), artificial intelligence (AI), and machine learning (ML), along with advances in synthetic biology and automation. The company was founded by Sean Brady and David L. Pompliano and is headquartered in New York, NY.

SV Health Investors LLC is a Venture Capital firm, a subsidiary of SV Health Investors LLP founded in 2006. SV Health Investors LLC is headquartered in Boston.

eFFECTOR Therapeutics Operations, Inc. discovers and develops translation regulators. It offers small molecule therapeutics that control gene expression for the treatment of cancer and other serious diseases. Its pipeline of translation regulators includes eFT508, eIF4E, and eIF4A. The company was founded by James R. Appleman, Kevin L. Eastwood, Siegfried Reich, Davide Ruggero, Kevan Shokat, and Stephen T. Worland in 2012 and is headquartered in San Diego, CA.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.